The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor—Positive Breast Cancer
Open accessAbstract
Purpose: To investigate the patterns and predictors of tamoxifen discontinuance throughout a 2-year period in a cohort of women 65 years or older with newly diagnosed, estrogen receptor (ER)–positive breast cancer, focusing on the role of patients’ beliefs about the risks and benefits of tamoxifen therapy. Subjects and Methods: We enrolled a convenience sample of women cared for in four geographic regions of the United States with stage 1 (≥ 1 cm), stage II, or stage IIIA disease; no prior history of breast cancer; and no simultaneously diagnosed second primary breast cancer. Data sources included medical records and telephone interviews with patients at 3, 6, 15, and 27 months following definitive surgery. Results: Of the 597 women with ER-positive tumors, 516 women (86%) were prescribed tamoxifen, and of these, 88 (17%) stopped taking tamoxifen during the 2-year follow-up period. Of the women who stopped taking tamoxifen, the majority (68%) took it for less than 1 year. Women with neutral or negative beliefs about the value of tamoxifen (3.0; 95% CI, 1.6 to 5.6) and those with positive nodes (odds ratio = 2.5; 95% CI, 1.0 to 6.3) were more likely to discontinue tamoxifen therapy. Conclusion: How women with early-stage breast cancer perceive the risks and benefits of tamoxifen therapy seems critical for sustaining adherence to adjuvant tamoxifen therapy. Interventions designed to educate women about the benefits and risks of tamoxifen therapy may help to reduce discontinuance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
SF-36 health survey: Manual and interpretation guide
Ware, J. (2003) · Medical Entomology and Zoology · Cited by 11,424
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Decision making: A psychological analysis of conflict, choice, and commitment
(1978) · Evaluation and Program Planning · doi:10.1016/0149-7189(78)90042-3 · Cited by 3,946
Stages of change and decisional balance for 12 problem behaviors.
Prochaska, J. O., Velicer, W. F., Rossi, J. S., Goldstein, M. G., Marcus, B. H., Rakowski, W., Fiore, C., Harlow, L. L., Redding, C. A., Rosenbloom, D., et al. (1994) · Health Psychology · doi:10.1037//0278-6133.13.1.39 · Cited by 2,469
Self-citationHorne, R., & Weinman, J. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(99)00057-4 · Cited by 2,201
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Patient adherence to treatment: three decades of research. A comprehensive review
Vermeire, E., Hearnshaw, H., Van Royen, P., & Denekens, J. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00363.x · Cited by 1,833
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Cited by
Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.-Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 828
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
“Lower perceived necessity of treatment, perception of less than optimal role in the treatment decision-making process, low social and/or material support, and lower decisional balance scores were negatively associated with tamoxifen adherence [24, 34, 36, 48].”
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569
Habel, L. A., Shak, S., Jacobs, M. K., Capra, A., Alexander, C., Pho, M., Baker, J., Walker, M., Watson, D., Hackett, J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1412 · Cited by 484
Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., & Asnis-Alibozek, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5451 · Cited by 482
Neugut, A. I., Subar, M., Wilde, E. T., Stratton, S., Brouse, C. H., Hillyer, G. C., Grann, V. R., & Hershman, D. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3179 · Cited by 354
McCowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604758 · Cited by 343
“1766 British Journal of Cancer (2008) 99(11), 1763 – 1768 & 2008 Cancer Research UK C lin ic a l S tu d ie s level and was similar to the figure reported by Fink et al (2004) at 2 years and Owusu et al (2008) at 5 years.”
ResultAdherence to tamoxifen over the five-year course
Lash, T. L., Fox, M. P., Westrup, J. L., Fink, A. K., & Silliman, R. A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9193-0 · Cited by 320
Self-citationOwusu, C., Buist, D. S. M., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., Quinn, V. P., Frost, F., Prout, M., Yood, M. U., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1022 · Cited by 304
Self-citationIntentional and non-intentional non-adherence to medication amongst breast cancer patients
Atkins, L., & Fallowfield, L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.004 · Cited by 300
Delays in Breast Cancer Diagnosis and Treatment by Racial/Ethnic Group
Gorin, S. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.20.2244 · Cited by 294
Early discontinuation of tamoxifen: A Lesson for oncologists
Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy, M. J. (2007) · Cancer · doi:10.1002/cncr.22485 · Cited by 279
Adherence to endocrine therapy for breast cancer
Chlebowski, R. T., & Geller, M. L. (2006) · Oncology · doi:10.1159/000100444 · Cited by 251
Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007) · Medical Care · doi:10.1097/01.mlr.0000257193.10760.7f · Cited by 245
Verbrugghe, M., Verhaeghe, S., Lauwaert, K., Beeckman, D., & Van Hecke, A. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.014 · Cited by 202
Adjuvant hormonal therapy use among insured, low-income women with breast cancer
Kimmick, G., Anderson, R., Camacho, F., Bhosle, M., Hwang, W., & Balkrishnan, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2419 · Cited by 198
Lin, C., Clark, R., Tu, P., Bosworth, H. B., & Zullig, L. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4317-2 · Cited by 160
Bender, C. M., Gentry, A. L., Brufsky, A. M., Casillo, F. E., Cohen, S. M., Dailey, M. M., Donovan, H. S., Dunbar-Jacob, J., Jankowitz, R. C., Rosenzweig, M. Q., et al. (2014) · Oncology Nursing Forum · doi:10.1188/14.onf.274-285 · Cited by 131
Cluze, C., Rey, D., Huiart, L., BenDiane, M. K., Bouhnik, A. D., Berenger, C., Carrieri, M. P., & Giorgi, R. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr330 · Cited by 133
Wu, E. Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., Coombs, J., Feng, W., & Cortes, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903396469 · Cited by 126
Understanding tamoxifen adherence in women with breast cancer: A qualitative study
Moon, Z., Moss‐Morris, R., Hunter, M. S., & Hughes, L. D. (2017) · British Journal of Health Psychology · doi:10.1111/bjhp.12266 · Cited by 112
Huiart, L., Ferdynus, C., & Giorgi, R. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2422-4 · Cited by 106
Brett, J., Fenlon, D., Boulton, M., Hulbert-Williams, N. J., Walter, F. M., Donnelly, P., Lavery, B., Morgan, A., Morris, C., & Watson, E. (2018) · European Journal of Cancer Care · doi:10.1111/ecc.12601 · Cited by 98
Huiart, L., Bouhnik, A.-D., Rey, D., Tarpin, C., Cluze, C., Bendiane, M. K., Viens, P., & Giorgi, R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.004 · Cited by 97
Sheppard, V. B., Faul, L. A., Luta, G., Clapp, J. D., Yung, R. L., Wang, J. H.-Y., Kimmick, G., Isaacs, C., Tallarico, M., Barry, W. T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.7367 · Cited by 91
Livaudais, J. C., Hershman, D. L., Habel, L., Kushi, L., Gomez, S. L., Li, C. I., Neugut, A. I., Fehrenbacher, L., Thompson, B., & Coronado, G. D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1762-1 · Cited by 93
“Although few studies have reported on racial/ethnic differences in adherence to adjuvant hormonal breast cancer therapy, a variety of other factors have been associated with non-adherence, including patient perception of low risk for recurrence [14], experience of adverse events from use [15–17], older patient age [18…”
BackgroundCahir, C., Guinan, E., Dombrowski, S. U., Sharp, L., & Bennett, K. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.05.013 · Cited by 84
Ziller, V., Kyvernitakis, I., Knöll, D., Storch, A., Hars, O., & Hadji, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-407 · Cited by 82
Toivonen, K., Williamson, T., Carlson, L., Walker, L., & Campbell, T. (2020) · Cancers · doi:10.3390/cancers13010107 · Cited by 77
Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy
Kimmick, G., Edmond, S. N., Bosworth, H. B., Peppercorn, J., Marcom, P. K., Blackwell, K., Keefe, F. J., & Shelby, R. A. (2015) · The Breast · doi:10.1016/j.breast.2015.06.010 · Cited by 72
Ayres, L. R., Baldoni, A. D. O., Borges, A. P. D. S., & Pereira, L. R. L. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9833-5 · Cited by 65
Neugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L., Leoce, N., Nathanson, S. D., Ambrosone, C. B., Bovbjerg, D. H., Mandelblatt, J. S., Magai, C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2066-9 · Cited by 63
“Adherence to HT once initiated is also associated with belief in the efficacy of the medication [21, 26] and with belief in the benefits of taking prescribed medications [36, 43–45].”
BackgroundInfluentialYu, K.-D., Zhou, Y., Liu, G.-Y., Li, B., He, P.-Q., Zhang, H.-W., Lou, L.-H., Wang, X.-J., Wang, S., Tang, J.-H., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2059-8 · Cited by 50
Wouters, H., Stiggelbout, A. M., Bouvy, M. L., Maatman, G. A., Van Geffen, E. C. G., Vree, R., Nortier, J. W., & Van Dijk, L. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.04.005 · Cited by 46
Metadata
- Authors
- Fink, A. K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-08-15
- Volume
- 22
- Issue
- 16
- Pages
- 3309-3315
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102314359
- Cited by
- 281
- References
- 25
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.